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Summary
 
Injury of the endothelial cells by the induction of apoptotic cell death may play an important
role in the pathophysiology of atherosclerosis and the progression of inflammatory diseases.
Here, we demonstrate an essential role for the ubiquitin-dependent proteasome complex in
stimulus-induced degradation of the antiapoptotic protein Bcl-2. Bcl-2 is specifically degraded
after stimulation of human endothelial cells with tumor necrosis factor (TNF)-
 
a
 
 in a process
that is inhibited by specific proteasome inhibitors. In addition, the mutation of the potential
ubiquitin-acceptor amino acids of Bcl-2 provides protection against TNF-
 
a
 
– and staurospo-
rine-induced degradation in vitro and in vivo. Moreover, mimicking phosphorylation of the
putative mitogen-activated protein (MAP) kinase sites of the Bcl-2 protein (Thr 56, Thr 74,
and Ser 87) abolishes its degradation, suggesting a link between the MAP kinase pathway to the
proteasome pathway. Finally, inhibition of Bcl-2 degradation either by suppressing ubiquitin-
dependent proteasomal degradation or by mimicking continuous phosphorylation of the puta-
tive MAP kinase sites in the Bcl-2 protein confers resistance against induction of apoptosis.
Thus, the degradation of Bcl-2 may unleash the inhibitory function of Bcl-2 over the apopto-
some and may thereby amplify the activation of the caspase cascade.
Key words: Bcl-2 • apoptosis • mitogen-activated protein kinase • endothelial cells • 
proteasome
 
A
 
poptosis, the programmed kind of cell death, is an im-
portant physiological process in the development and
homeostasis of multicellular organisms. Apoptotic cell death is
characterized by a common pattern of morphological alter-
ations such as nuclear condensation, membrane blebbing, and
DNA fragmentation. The derangement of apoptosis either by
depression of this suicidal program or by an overstimulation
may be linked to pathophysiological disorders such as cancer
or neurodegenerative diseases (1). Importantly, injury of the
endothelial monolayer by the induction of apoptotic cell death
may play an important role in the pathophysiology of athero-
sclerosis and the progression of inflammatory diseases (2–6).
The signals leading to apoptotic cell death have been
mainly discovered in the nematode 
 
Caenorhabditis elegans
 
,
but are highly conserved among species, with at least three
classes of proteins playing important roles encoded by the
C. 
 
elegans
 
 cell death (Ced)
 
1
 
 gene, ced-3, ced-4, and ced-9
(7, 8). The mammalian homologues of the ced-3 gene are
cysteine proteases with aspartic acid specificity (caspases).
Caspases are the key effector proteins of apoptosis in mam-
malian cells (9). The mammalian homologues of 
 
ced-9
 
 have
been identified and comprise proteins of the Bcl-2 family.
Bcl-2, Mcl-1, and Bcl-X
 
L
 
 have been shown to promote
cell survival, whereas other members of the Bcl-2 family,
such as Bax, Bad, or Bcl-X
 
S
 
, exhibit proapoptotic effects
(10, 11). The mammalian homologue of Ced-4 has re-
cently been identified as Apaf-1 (12). Two distinctly differ-
ent pathways of caspase activation and apoptosis have been
delineated (13). First, ligation of death receptors such as Fas
recruits adaptor proteins and procaspase molecules like
caspase-8, resulting in direct activation of the caspase cas-
cade (14). In the second pathway, various forms of cellular
stress trigger mitochondrial release of cytochrome C, which
binds to Apaf-1, leading to the activation of downstream
caspases (15, 16). Thus, although both pathways converge
on the activation of the downstream caspases, the involve-
ment of cytochrome C released from mitochondria intro-
duces a fundamental difference. Importantly, Bcl-2 has
been shown to prevent cytochrome C release from mito-
 
1
 
Abbreviations used in this paper:
 
 ALLN, 
 
N
 
-acetyl-leucinyl-leucinyl-nor-
leucinal-H; Ced, 
 
Caenorhabditis elegans
 
 cell death gene; ERK, extracellular
signal–regulated kinase; HUVEC, human umbilical vein endothelial cell;
MAP, mitogen-activated protein; MKP, mitogen-activated protein kinase
phosphatase; Z-LLL-H, carbobenzoxyl-leucinyl-leucinyl-leucinal-H. 
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chondria (17, 18). Thus, the model currently proposed to
account for the antiapoptotic action of Bcl-2 is that Bcl-2
interferes with activation of the cytochrome C/Apaf-1
pathway by stabilizing the mitochondrial membrane. In-
flammatory processes or heart failure are associated with a
dramatic decrease of Bcl-2 protein levels in vivo (19–21),
which correlates with in vitro studies demonstrating a post-
transcriptional reduction of Bcl-2 (22, 23). Thus, posttran-
scriptional regulation of Bcl-2 may significantly affect the
resistance of cells to apoptosis induction.
The degradation of intracellular proteins is mainly medi-
ated by the ubiquitin-dependent proteasome complex (24).
Thereby, proteins are targeted for degradation by the cova-
lent attachment of ubiquitin, a ubiquitously expressed 76–
amino acid polypeptide (25, 26). Initially, the degradation
of proteins by the proteasome complex was regarded as a
mechanism for destruction of misfolded or damaged pro-
teins. However, it is now clear that proteasome-mediated
degradation plays a crucial role in regulating various essen-
tial cell functions (27). Indeed, the ubiquitin-dependent pro-
teasome pathway controls the ordered degradation of pro-
teins involved in cell cycle control, and further regulates
cell survival by degradation of p53 (28, 29). Moreover, sev-
eral other important signaling pathways, such as the activa-
tion of transcription factors, are controlled via protein deg-
radation by the proteasome complex (30, 31).
In this study, we examined the role of Bcl-2 degradation
in apoptosis signaling. We demonstrated that Bcl-2 is spe-
cifically degraded in human umbilical vein endothelial cells
(HUVECs) or HeLa cells undergoing stimulus-dependent
apoptosis. The enzyme responsible for Bcl-2 degradation was
identified as the ubiquitin-dependent proteasome complex,
and caspases were not involved. Characterization of the
signaling events triggering Bcl-2 degradation indicates a link
between the mitogen-activated protein (MAP) kinase path-
way and the proteasome pathway. Most important, we
provide evidence that inhibition of Bcl-2 degradation ei-
ther by suppressing ubiquitin-dependent proteasomal deg-
radation or by mimicking continuous phosphorylation of
MAP kinase sites in the Bcl-2 protein confers protection
against TNF-
 
a
 
– or staurosporine-mediated apoptosis.
 
Materials and Methods
 
Cell Culture.
 
HUVECs were purchased from Cell Systems/
Clonetics and cultured in endothelial basal medium supplemented
with hydrocortisone (1 
 
m
 
g/ml), bovine brain extract (3 
 
m
 
g/ml),
gentamicin (50 
 
m
 
g/ml), amphotericin B (50 
 
m
 
g/ml), epidermal
growth factor (10 
 
m
 
g/ml), and 10% FCS until the third passage.
 
Western Blot Analysis and Immunoprecipitation.
 
HUVECs (5 
 
3
 
10
 
5
 
 cells) were incubated for the time indicated with TNF-
 
a
 
, and
homogenates were obtained as described previously (3); Western
blots were performed with anti–Bcl-2 antibody (Boehringer
Mannheim) or anti-myc antibody (Santa Cruz Biotechnology).
For detection of phosphorylated extracellular signal–regulated ki-
nase (ERK), proteins were isolated as described previously (32),
and blots were probed with phospho-specific ERK1/2 (New Eng-
land Biolabs). For immunoprecipitation, proteins (3 mg) were in-
cubated with anti-myc antibody (1 
 
m
 
g/ml; Santa Cruz Biotech-
nology) at 4
 
8
 
C for 4 h and bound to A/G-PLUS–agarose beads
(Santa Cruz Biotechnology). Western blot analysis was performed
using antiubiquitin antibody (Sigma Chemical Co.).
 
Plasmid Transfection.
 
Human Bcl-2 was amplified by PCR
with oligonucleotides containing EcoRV and HindIII restriction
sites and cloned into the respective sites of pcDNA3.1(
 
2
 
)Myc-
His (Invitrogen) under the transcriptional control of the CMV
promoter. MAP kinase phosphatase (MKP)-3 was cloned after
PCR amplification with oligonucleotides containing EcoRV and
BamHI restriction sites into the pcDNA3.1(
 
2
 
)Myc-His vector.
Bcl-2 mutants and the MKP-3 mutant were obtained by PCR-
directed mutagenesis or by site-directed mutagenesis (Stratagene).
Clones with verified sequences were transfected in HeLa cells or
HUVECs. HeLa cells were transfected with plasmids encoding
wild-type Bcl-2 or mutated Bcl-2 by the lipofectamine proce-
dure (GIBCO BRL) and selected with 0.5 mg/ml G-418 for 6 d
before stimulation of apoptosis. Heterogenous populations of the
stably transfected cells were used to avoid any possible clonal
variations. HUVECs were transfected with 3 
 
m
 
g pcDNA3.1 plas-
mid encoding the corresponding sequence as described previ-
ously (32). For the detection of apoptosis, HUVECs were co-
transfected with 
 
b
 
-galactosidase. In brief, 150 
 
m
 
l medium was
mixed with 3 
 
m
 
g plasmids (1 
 
m
 
g pcDNA3.1-lacZ and 2 
 
m
 
g
pcDNA3.1–Bcl-2) and 30 
 
m
 
l Superfect (Qiagen) and incubated
for 10 min at room temperature. During the incubation time,
medium was removed from the cell culture plates, and HUVECs
were washed twice in medium without FCS. 1 ml medium was
then added to the plasmid-Superfect mixture, and HUVECs
were incubated with this mixture for 3 h at 37
 
8
 
C. After the incu-
bation, culture medium was removed, 3 ml fresh complete me-
dium was added, and HUVECs were incubated for 36 h to allow
protein expression. Transfected cells were identified by 
 
b
 
-galac-
tosidase staining (32). Viable versus dead stained cells were
counted by two blinded investigators, and results were expressed
as (dead cells/viable cells) 
 
3
 
100. In addition, necrotic cell death
was excluded by measuring lactate dehydrogenase (LDH) release,
thus indicating that the cell death of the transfected cells is caused
by apoptosis. The transfection efficiency with 3 
 
m
 
g pcDNA3.1–
 
b
 
-galactosidase was 24 
 
6 
 
4%.
 
Pulse–Chase Analysis.
 
HUVECs were starved in RPMI me-
dium without methionine and cysteine for 1 h, then metabolically
labeled with [
 
35
 
S]methionine and [
 
35
 
S]cysteine for 3 h. HUVECs
were then chased in nonradioactive medium for the time periods
indicated, in the presence or absence of TNF-
 
a
 
. Cells were
washed twice with PBS and lysed in radioimmunoprecipitation
assay (RIPA) buffer (150 mM NaCl, 1% NP-40, 0.5% deoxy-
cholic acid, 0.1% SDS, and 50 mM Tris-HCl, pH
 
 
 
8) at 4
 
8
 
C for
20 min. Samples containing equal amounts of protein were pre-
cleared with anti–rabbit IgG for 30 min at 4
 
8
 
C, immunoprecipi-
tated with an anti-myc antibody, and resolved on 12% SDS-
PAGE. The gel was dried and exposed to x-ray film.
 
In Vitro Translation.
 
pcDNA3.1–Bcl-2 wild-type or mutants
were in vitro transcribed/translated using the T7 polymerase kit
(Promega Corp.) in the presence of [
 
35
 
S]methionine. Degrada-
tion was then determined by incubation of 
 
35
 
S-labeled Bcl-2 with
TNF-
 
a
 
–treated HUVEC homogenates (70 
 
m
 
g) at 37
 
8
 
C.
 
Cell Death Analysis.
 
DNA fragmentation was demonstrated
by the typical DNA laddering and quantified by an ELISA
specific for histone-associated DNA fragments as described pre-
viously (3). For morphological staining of nuclei, cells were
centrifuged (10 min, 700 
 
g
 
), fixed in 4% formaldehyde, and
stained with 4
 
9
 
,6-diamidino-phenylindole (DAPI; 0.2 
 
m
 
g/ml in 
1817
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10 mM Tris-HCl, pH
 
 
 
7, 10 mM EDTA, 100 mM NaCl) for
20 min.
 
Phosphorylation.
 
For detection of in vitro phosphorylation of
Bcl-2 by MAP kinase, COS cells were transfected with myc-
tagged Bcl-2 wild-type or mutant, and overexpressed proteins
were immunoprecipitated with anti-myc antibodies. The immu-
noprecipitates were incubated at 30
 
8
 
C in 30 
 
m
 
l kinase reaction
mixture containing 25 mM Tris (pH 7.5), 5 mM 
 
b
 
-glycero-
phosphate,  0.1 mM Na
 
3
 
VO
 
4
 
, 2 mM dithiothreitol, 10 mM
MgCl
 
2
 
, 50 
 
m
 
M ATP, 5 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP with or without 20 ng
activated MAP kinase ERK2 (New England Biolabs) for 30 min.
The reaction was terminated by addition of SDS loading dye, and
samples were subjected to a 12% SDS-PAGE and analyzed by
PhosphorImager (Molecular Dynamics).
 
Results and Discussion
 
Selective Degradation of Bcl-2 by Apoptotic Stimuli.
 
Treat-
ment of HUVECs with the proapoptotic stimuli TNF-
 
a
 
,
staurosporine, and doxorubicin resulted in a profound
time- and dose-dependent reduction of Bcl-2 protein levels
(Fig. 1, A and B; data not shown). Reduction of Bcl-2 pro-
tein levels clearly preceded the induction of apoptosis (Fig.
1 B). In contrast, TNF-
 
a
 
 did not affect Bax or Bcl-X
 
L
 
 pro-
tein levels (Fig. 1 C). Reduced Bcl-2 protein levels in re-
sponse to various apoptotic stimuli were also observed in
HeLa cells, illustrating that the effects are not unique for
endothelial cells (data not shown). Bcl-2 mRNA levels
Figure 1. TNF-a–induced Bcl-2 degradation. (A) Time-dependent reduction of Bcl-2 in TNF-a–stimulated HUVECs. Western blot analysis of Bcl-2
protein after incubation of HUVECs with TNF-a (100 ng/ml) for the time periods indicated. Blots were reprobed with actin as a loading control. (B) Ef-
fect of TNF-a on Bcl-2 protein levels and apoptosis. Bcl-2 protein levels were determined by densitometric analysis of Bcl-2 Western blots after incuba-
tion of HUVECs with TNF-a for the time periods indicated. Apoptosis was measured by an ELISA specific for histone-associated DNA fragments (n 5 5;
mean 6 SD). (C) Western blot analysis for Bax and Bcl-XL after incubation of HUVECs with TNF-a (100 ng/ml) for 6 or 12 h. (D) Pulse–chase experi-
ment. HUVECs were transiently transfected with myc-tagged Bcl-2 for 24 h, then chased for 30 min before incubation for the indicated times in the pres-
ence or absence of TNF-a, and Bcl-2 was immunoprecipitated with an anti-myc antibody. (E) Formation of Bcl-2 ubiquitin adducts. HUVECs were
transfected with myc-tagged wild-type (wt) Bcl-2 or the Bcl-2 mutant (mt) lacking all lysine residues (K17R, K22R, K218R, and K239R). After stimula-
tion with TNF-a for 2.5 h, the expressed Bcl-2 protein was immunoprecipitated with anti-myc antibodies, and ubiquitination was detected by Western
blotting (WB) with antiubiquitin antibodies. Reprobe of the Western blot with antibodies against myc (lower panel) serves as control for expression and
immunoprecipitation. (F and G) Effect of the proteasome inhibitors Z-LLL-H (20 mM), lactacystin (25 mM), and ALLN (5 mg/ml) on TNF-a–induced
(100 ng/ml, 6 h) or staurosporine-induced (1 mM, 6 h) Bcl-2 degradation (n 5 4; mean 6 SD). 
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were essentially unchanged after TNF-
 
a
 
–induced apoptosis
(data not shown), suggesting a posttranscriptional effect on
Bcl-2 protein. Pulse–chase experiments demonstrated that
an increased rate of Bcl-2 protein degradation rather than a
reduced protein biosynthesis accounts for the decline of
Bcl-2 protein levels (Fig. 1 D). Thus, TNF-
 
a
 
, staurospo-
rine, and doxorubicin appear to stimulate the selective deg-
radation of Bcl-2 by a posttranscriptional mechanism.
 
The Ubiquitin-dependent Proteasome Pathway Mediates Bcl-2
Degradation.
 
The ubiquitin-dependent proteasome path-
way plays an important role in the degradation of regula-
tory proteins and thereby fulfills important functions in cell
cycle regulation and signal transduction (30, 31). The ubiq-
uitin-dependent pathway requires the covalent conjugation
of ubiquitin with 
 
e
 
-amino groups of lysine residues within
the target proteins (24). Indeed, TNF-
 
a
 
 stimulated the ubiq-
uitination of transiently expressed myc-tagged Bcl-2 (Fig.
1 E, lane 4). In contrast, ubiquitination was significantly pre-
vented in a Bcl-2 construct, where all four lysine residues
were mutated to arginine (Fig. 1 E, lane 5). Moreover, the
proteasome inhibitors lactacystin (33, 34), carbobenzoxyl-
leucinyl-leucinyl-leucinal-H (Z-LLL-H [31]), and 
 
N
 
-acetyl-
leucinyl-leucinyl-norleucinal-H (ALLN [31]) completely
prevented TNF-
 
a
 
– as well as staurosporine-induced degra-
dation of Bcl-2 in vivo (Fig. 1, F and G).
Similar results were obtained in an in vitro assay system
in which the cleavage of 
 
35
 
S-labeled Bcl-2 by homogenates
of TNF-
 
a
 
–treated HUVECs was assessed (Fig. 2 A). The
proteolytic cleavage of 
 
35
 
S-labeled Bcl-2 was abolished by
the specific proteasome complex inhibitors (Fig. 2 B). More-
Figure 2. Characterization of TNF-a–induced Bcl-2 degradation in vitro. (A) Comparison of Bcl-2 cleavage activity of HUVEC homogenates, which
were prestimulated for 2.5 h with or without TNF-a. 35S-labeled Bcl-2 was coincubated in the presence or absence of HUVEC homogenates for 3 h at
4 or 378C. (B) Inhibition of TNF-a–stimulated 35S–Bcl-2 cleavage activity in HUVEC homogenates by specific proteasome inhibitors (Z-LLL-H, 40
mM; lactacystin, 50 mM; ALLN, 5 mg/ml), caspase-3 inhibitor (Ac-DEVD-CHO, 100 mM), serine protease inhibitors (PMSF, 5 mM; aprotinin, 1 mg/
ml; leupeptin, 1 mg/ml), aspartic protease inhibitor (pepstatin, 1 mg/ml), or metalloprotease inhibitor (EDTA, 10 mM) or ATPgS (2 mM). Densitomet-
ric data are expressed as mean 6 SEM (n 5 4). (C) Illustration of mutants and reduction of Bcl-2 levels after incubation with TNF-a–prestimulated ho-
mogenates at 378C compared with 48C (mean 6 SEM; n 5 3). Mutated (mt) and wild-type (wt) lysine residue are indicated. (D) Autoradiographs dem-
onstrating the proteolytic cleavage of selected mutants induced by TNF-a–prestimulated HUVEC homogenates, when incubated for 3 h at 4 or 378C.1819 Dimmeler et al.
over, the degradation of Bcl-2 was inhibited by ATPgS
(Fig. 2 B), which is a typical feature of the proteasome
complex (35). Furthermore, mutating all four lysine resi-
dues (mt 1) precluding ubiquitination as shown in Fig. 1 E
completely abrogated the degradation of Bcl-2 (Fig. 2, C
and D). Mutation of three out of four lysine residues (mt 2–5)
led to a partial inhibition of Bcl-2 degradation (Fig. 2, C
and D). In contrast, caspase inhibitors (Ac-DEVD-CHO,
Ac-YVAD-CHO) or inhibitors of serine-, aspartate-, or
metalloproteases did not prevent Bcl-2 degradation (Fig. 2 B;
data not shown). Mutation of the caspase cleavage site
Asp34 of Bcl-2 (36) did not confer resistance against TNF-
a–mediated Bcl-2 degradation in vitro or in vivo (mt 10,
Fig. 2, C and D; data not shown). Additionally, mutation
of the loop region (amino acid residues 35–79) of Bcl-2 did
not affect stimulus-dependent degradation (mt 8, Fig. 2, C
and D). These results indicate that the ubiquitin-dependent
proteasome pathway is required for TNF-a–induced deg-
radation of Bcl-2.
Inhibition of the Ubiquitin-dependent Proteasome Pathway Con-
fers Resistance to Proapoptotic Stimuli. To establish a func-
tional role of stimulus-dependent degradation of Bcl-2 on
apoptosis induction, the degradation-resistant Bcl-2 mutant
(mt 1) was transfected into HUVECs. TNF-a–induced
apoptosis was significantly reduced in cells expressing the
corresponding Bcl-2 mutant, whereas overexpression of
wild-type Bcl-2 provided less protection (Fig. 3, A and B).
Likewise, expressing the degradation-resistant Bcl-2 mutant
in HeLa cells significantly reduced TNF-a–induced apop-
tosis by 71 6 6% in Bcl-2 mutant transfected cells com-
pared with 41 6 0.7% reduction in wild-type Bcl-2 trans-
fected cells (P , 0.05), indicating that the observed effects
are not unique to endothelial cells. In contrast, overexpres-
sion of the caspase cleavage–resistant D34A Bcl-2 mutant
did not prevent TNF-a–induced apoptosis in HUVECs
(19 6 3 compared with 20.7 6 4% apoptosis in Bcl-2
wild-type transfected cells). Moreover, apoptosis induced
by staurosporine was dramatically inhibited by overexpres-
sion of the degradation-resistant Bcl-2 mutant, which res-
cued almost all cells (Fig. 3 C). The different effects of the
Bcl-2 mutants were not due to enhanced basal expression as
demonstrated by Western blot analysis (Fig. 3, B and C).
Thus, these results establish inhibition of the ubiquitin-
dependent degradation of Bcl-2 as an extremely potent
mechanism to suppress stimulus-induced apoptosis induction.
Figure 3. Influence of Bcl-2 degradation on apoptosis. (A and B)
HUVECs were transiently cotransfected with pcDNA3.1-myc–wild-type
Bcl-2 (Bcl-2 wt; 2 mg), pcDNA3.1-myc–Bcl-2 mutant lacking all four
lysine residues (Bcl-2 mt; 2 mg), or control vector (pcDNA3.1 without in-
sert; 2 mg) and pcDNA3.1-lacZ (1 mg). After incubation for 24 h to allow
expression of the proteins, apoptosis was induced by incubation with TNF-a
(100 ng/ml) for 18 h. Transfected cells were identified by b-galactosidase
staining. Top panel (enlargement 1:10) shows a representative overview,
with arrows indicating the dead cells. Dead cells were additionally analyzed at
1:40 magnification (top right panel) to confirm the morphological alterations
typical for apoptotic cell death. (B) Dead versus viable cells were counted un-
der phase–contrast by two independent investigators in a total number of 600
cells (data are mean 6 SEM, n 5 4–6; *P , 0.05 vs. Bcl-2 wt 1 TNF; **P ,
0.05 vs. Bcl-2 mt 1 TNF). As shown in the insert, expression of the myc-
tagged Bcl-2 wild-type and Bcl-2 mutant was controlled by Western blot
with anti-myc antibodies. (C) Effect of Bcl-2 wild-type or Bcl-2 mutant lack-
ing all four lysine residues on staurosporine-induced apoptosis. HUVECs
were transiently transfected with the vectors described above, and apoptosis
was stimulated with staurosporine (1 mM) for the indicated times. The basal
expression and the degradation of the transfected Bcl-2 protein were deter-
mined by Western blot with anti-myc antibodies, as shown in the insert.1820 Ubiquitin-dependent Degradation of Bcl-2
Dephosphorylation of Bcl-2 Signals Ubiquitin-dependent Deg-
radation. Targeting of proteins for ubiquitin-dependent
degradation is often regulated by phosphorylation or dephos-
phorylation of the target protein (27, 30). Since previous
studies suggested that reduction of the activity of MAP ki-
nases ERK1/2 may be linked to dephosphorylation of Bcl-2
(37), we investigated whether the MAP kinase pathway is
involved in the Bcl-2 degradation process. Prolonged incu-
bation with TNF-a induced a drastic dephosphorylation and
deactivation of ERK1/2 (Fig. 4 A; data not shown). More-
over, inhibition of ERK1/2 activity by the MAP kinase/ERK
kinase (MEK) inhibitor PD98059 triggered the degradation of
Bcl-2 (Fig. 4 B) and induced apoptotic cell death (data not
shown), suggesting that inhibition of ERK1/2 may trigger the
degradation of Bcl-2. Furthermore, activated ERK induced
phosphorylation of Bcl-2 in vitro (Fig. 4 C). ERK-induced
Bcl-2 phosphorylation was prevented by mutation of the three
residues matching the consensus sequence for the putative
MAP kinase sites (P-X-X-T/S-P) in Bcl-2 into alanine
(Fig. 4 C), demonstrating the specificity of the reaction.
To test whether phosphorylation of Bcl-2 might prevent
its degradation, we specifically mutated the three MAP kinase
sites (P-X-X-T/S-P) into phospho-mimetic aspartic acid res-
idues, which mimics continuous phosphorylation of the pro-
tein. Expression of the phospho-mimetic mutants completely
prevented TNF-a–induced Bcl-2 degradation and apoptosis
(Fig. 4 D). Thus, mimicking phosphorylation of putative
MAP kinase sites within Bcl-2 is associated with complete in-
hibition of TNF-a–induced degradation. Finally, we tried to
more precisely characterize the role of ERK to interfere with
Bcl-2 degradation. Therefore, we assessed the effect of the
ERK-specific phosphatase MKP-3. Since MKP-3 is exclu-
sively located in the cytosolic compartment of cells, whereas
MKP-1 and MKP-2 are localized in the nuclei (38, 39),
MKP-3 may be one possible effector enzyme inducing the
dephosphorylation of ERK. Overexpression of MKP-3 not
only reduced ERK1/2 activity as described previously (data
not shown; reference 38) but also induced degradation of
wild-type Bcl-2 and subsequent apoptotic cell death (Fig.
4 E). In contrast, the phospho-mimetic Bcl-2 mutant or the
Bcl-2 construct lacking all four lysine residues was resistant to
MKP-3–triggered degradation (Fig. 4 E).
Taken together, ubiquitin-dependent proteolytic degra-
dation decreases Bcl-2 protein levels and thereby renders
Figure 4. Involvement of MAP
kinases in regulating Bcl-2 deg-
radation. (A) Effect of TNF-a
on ERK1/2 phosphorylation in
HUVECs. ERK1/2 phosphory-
lation was determined by West-
ern blot with a phospho-specific
ERK1/2 antibody. The reduc-
tion of phosphorylation corre-
lated with reduced enzyme ac-
tivity (data not shown). Blots
were reprobed with actin as a
loading control. (B) Effect of
PD98059 (10 mM; 12 h) on deg-
radation of Bcl-2 wild-type (wt)
and Bcl-2 mutant (mt) lacking all
four lysine residues in HUVECs.
(C) Phosphorylation of Bcl-2 by
active ERK. Bcl-2 wild-type or
Bcl-2 mutant lacking the puta-
tive MAP kinase acceptor amino
acids A1/A2/A3 (T56A, T74A,
S87A) were expressed in COS-7
cells, and myc-tagged Bcl-2 was
immunoprecipitated. The im-
munoprecipitates or the control
substrate Elk were incubated
with [32P]ATP and active MAP
kinase for 30 min, then resolved
on 12% SDS gels. An autoradio-
graph of the SDS gel is shown.
(D) Effect of phospho-mimetic
mutation of MAP kinase phos-
phorylation sites of Bcl-2 (P1,
T56D; P2, T74D; P3, S87D) on
TNF-a–stimulated Bcl-2 degra-
dation and apoptosis. Plasmids (pcDNA3.1) encoding the myc-tagged mutants were transfected in HUVECs for 24 h to allow protein expression before
stimulation with TNF-a for 12 h. Blots were reprobed with actin as a loading control. For detection of apoptosis, HUVECs were transiently cotrans-
fected with 2 mg plasmids and 1 mg pcDNA3.1–b-galactosidase. Dead versus viable cells were counted under phase–contrast by two independent inves-
tigators in a total number of 600 cells (*P , 0.05 vs. vector 1 TNF and Bcl-2 wt 1 TNF; data are mean 6 SEM, n 5 3). (E) Effect of MKP-3 overex-
pression on Bcl-2 degradation in HUVECs. Plasmids (pcDNA3.1) encoding MKP-3 or control vector were transiently overexpressed in combination
with the myc-tagged Bcl-2 wild-type or Bcl-2 mutants (mt: K17R, K22R, K218R, K239R, or P1/P2/P3: T56D, T74D, S87D). After 24 h, Bcl-2 wild-
type or mutant protein levels were detected by Western blot with anti-myc antibodies. A reprobe with actin serves as loading control.1821 Dimmeler et al.
cells susceptible for apoptotic stimuli. Moreover, our data
may suggest that dephosphorylation of the putative MAP
kinase sites targets Bcl-2 for ubiquitin-dependent degrada-
tion, whereas simulation of continuous phosphorylation of the
putative MAP kinase phosphorylation sites of Bcl-2 not only
abolishes its degradation, but—more important—confers
resistance to stimulus-induced apoptosis. Bcl-2 is believed
to control the activation of the caspase cascade by participa-
tion in a multiprotein “apoptosome” ensemble involving
Apaf-1, cytochrome C, and caspase-9 (40). Thus, degrada-
tion of Bcl-2 may unleash the inhibitory function of Bcl-2
over the apoptosome. This is further evidenced by the
finding that antisense-induced selective downregulation of
Bcl-2 triggers the release of cytochrome C from the mito-
chondria (data not shown). Thus, ubiquitin-dependent
degradation of Bcl-2 may represent an alternative pathway
to amplify the caspase cascade. The activation of the ubiq-
uitin-dependent proteasome complex leading to selective
degradation of Bcl-2 not only appears to be a key signaling
pathway used by TNF-a to amplify its potency to induce
apoptosis, but may be involved in apoptosis signaling in all
cells, where the mitochondrial amplification loop is impor-
tant. Moreover, since the endothelium plays a pivotal role
as a gatekeeper during inflammation, the selective down-
regulation of the antiapoptotic Bcl-2 by inflammatory cyto-
kines such as TNF-a may significantly affect endothelial
integrity and thus the progression of inflammatory diseases
such as atherosclerosis. Inhibition of the signaling pathways
involved in Bcl-2 degradation may not only provide in-
sights into the pathophysiological role of Bcl-2 degrada-
tion, but may also have important novel therapeutic impli-
cations in disease states with deregulated apoptosis.
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